Angiotech Pharmaceuticals Sells Interventional Products Business

04.2013

Irell & Manella LLP represented Angiotech Pharmaceuticals, Inc., a global specialty pharmaceutical and medical device company, in connection with the $362.5 million sale of its interventional products business to Argon Medical Devices, Inc. The transaction closed on April 12, 2013.

The core deal team included Sandra Kanengiser.

Irell & Manella previously represented Angiotech Pharmaceuticals in connection with the sale of its Quill™ knotless tissue closure product line to Ethicon, a subsidiary of Johnson & Johnson, for a purchase price that could reach $62 million.